Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Flying Solo As A Pure Biopharma After Mead Johnson Spin Out

This article was originally published in The Pink Sheet Daily

Executive Summary

Decision to split off the nutritionals unit - Bristol's last diversified business - reflects management's improved confidence in the biopharma business and strength of Mead Johnson's stock price.

You may also be interested in...

Ahead Of Schedule, Pfizer Prepares To Set Zoetis Free In Stock Swap

The Big Pharma intends to loosen its leash on its former animal health business come June when Pfizer shareholders will be given an option to swap their shares for Zoetis stock. Meanwhile, Pfizer continues its strategy to shift its focus back to the core pharmaceutical business.

Financings Of The Fortnight Expects An Increase In Life Sciences IPOs In 2013

Plus news of recent financings by the Pfizer animal health spin-out Zoetis, Bone Therapeutics, Ariad Pharmaceuticals and Foresight Capital Management.

Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE

Zoetis makes its debut on the public stock exchange, garnering the highest priced IPO since Facebook began trading last year.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts